Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/11/22
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsBusiness Wire • 08/11/22
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency DisorderBusiness Wire • 07/28/22
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 MillionBusiness Wire • 07/14/22
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022Business Wire • 07/13/22
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status EpilepticusBusiness Wire • 06/08/22
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesBusiness Wire • 05/18/22
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial ResultsBusiness Wire • 05/12/22
Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/05/22
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status EpilepticusBusiness Wire • 05/05/22
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022Business Wire • 04/20/22
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial ResultsBusiness Wire • 04/14/22
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit FacilityBusiness Wire • 03/31/22
Marinus Pharmaceuticals, Inc. (MRNS) CEO Dr. Scott Braunstein on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/21/22
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 03/21/22
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency DisorderBusiness Wire • 03/18/22
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical TrialsBusiness Wire • 02/22/22
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022Business Wire • 02/16/22
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory UpdateBusiness Wire • 02/03/22
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C.Business Wire • 01/05/22